Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Rossignol

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
The Journal of Pharmacology and Experimental Therapeutics|October 21, 2003
Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]Melvyn Lynn, Y Nancy Wong, Janice L Wheeler, et al.
Pharmacological Research|June 6, 2022
Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal diseaseP Rossignol, J Silva-Cardoso, M N Kosiborod, et al.
Scandinavian Journal of Rheumatology|April 21, 2023
Unsupervised clustering to differentiate rheumatoid arthritis patients based on proteomic signaturesM B Ferreira, M Kobayashi, R Q Costa, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 24, 2002
A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activityLynn D Hawkins, Sally T Ishizaka, Pamela McGuinness, et al.
Nature|May 3, 2013
The TLR4 antagonist Eritoran protects mice from lethal influenza infectionKari Ann Shirey, Wendy Lai, Alison J Scott, et al.
European Heart Journal Open|January 5, 2023
NT-proBNP and stem cell factor plasma concentrations are independently associated with cardiovascular outcomes in end-stage renal disease hemodialysis patientsP Rossignol, K Duarte, E Bresso, et al.
JAMA|March 21, 2013
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trialSteven M Opal, Pierre-Francois Laterre, Bruno Francois, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
The Journal of Pharmacology and Experimental Therapeutics|October 21, 2003
Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]Melvyn Lynn, Y Nancy Wong, Janice L Wheeler, et al.
Pharmacological Research|June 6, 2022
Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal diseaseP Rossignol, J Silva-Cardoso, M N Kosiborod, et al.
Scandinavian Journal of Rheumatology|April 21, 2023
Unsupervised clustering to differentiate rheumatoid arthritis patients based on proteomic signaturesM B Ferreira, M Kobayashi, R Q Costa, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 24, 2002
A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activityLynn D Hawkins, Sally T Ishizaka, Pamela McGuinness, et al.
Nature|May 3, 2013
The TLR4 antagonist Eritoran protects mice from lethal influenza infectionKari Ann Shirey, Wendy Lai, Alison J Scott, et al.
European Heart Journal Open|January 5, 2023
NT-proBNP and stem cell factor plasma concentrations are independently associated with cardiovascular outcomes in end-stage renal disease hemodialysis patientsP Rossignol, K Duarte, E Bresso, et al.
JAMA|March 21, 2013
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trialSteven M Opal, Pierre-Francois Laterre, Bruno Francois, et al.
Pageof 8